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Abstract: Variation in utilization of healthcare services is influenced by patient, provider and healthcare
system characteristics. It could also be related to the evidence supporting their use, as reflected in
the availability and strength of recommendations in clinical guidelines. In this study, we analyzed the
geographic variation of colorectal, breast and prostate cancer screening utilization in Switzerland and
the influence of available guidelines and different modifiers of access. Colonoscopy, mammography and
prostate specific antigen (PSA) testing use in eligible population in 2014 was assessed with administrative
claims data. We ran a multilevel multivariable logistic regression model and calculated Moran’s I and
regional level median odds ratio (MOR) statistics to explore residual geographic variation. In total, an
estimated 8.1% of eligible persons received colonoscopy, 22.3% mammography and 31.3% PSA testing.
Low deductibles, supplementary health insurance and enrollment in a managed care plan were associated
with higher screening utilization. Cantonal breast cancer screening programs were also associated with
higher utilization. Spatial clustering was observed in the raw regional utilization of all services, but
only for prostate cancer screening in regional residuals of the multilevel model. MOR was highest for
prostate cancer screening (1.24) and lowest for colorectal cancer screening (1.16). The reasons for the
variation of the prostate cancer screening utilization, not recommended routinely without explicit shared
decision-making, could be further investigated by adding provider characteristics and patient preference
information. This first cross-comparison of different cancer screening patterns indicates that the strength
of recommendations, mediated by specific health policies facilitating screening, may indeed contribute to
variation.
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Variation in utilization of healthcare services is influenced by patient, provider and health-
care system characteristics. It could also be related to the evidence supporting their use, as
reflected in the availability and strength of recommendations in clinical guidelines. In this
study, we analyzed the geographic variation of colorectal, breast and prostate cancer
screening utilization in Switzerland and the influence of available guidelines and different
modifiers of access. Colonoscopy, mammography and prostate specific antigen (PSA) test-
ing use in eligible population in 2014 was assessed with administrative claims data. We ran
a multilevel multivariable logistic regression model and calculated Moran’s I and regional
level median odds ratio (MOR) statistics to explore residual geographic variation. In total, an
estimated 8.1% of eligible persons received colonoscopy, 22.3%mammography and 31.3%
PSA testing. Low deductibles, supplementary health insurance and enrollment in a man-
aged care plan were associated with higher screening utilization. Cantonal breast cancer
screening programs were also associated with higher utilization. Spatial clustering was
observed in the raw regional utilization of all services, but only for prostate cancer screening
in regional residuals of the multilevel model. MOR was highest for prostate cancer screening
(1.24) and lowest for colorectal cancer screening (1.16). The reasons for the variation of the
prostate cancer screening utilization, not recommended routinely without explicit shared
decision-making, could be further investigated by adding provider characteristics and
patient preference information. This first cross-comparison of different cancer screening
patterns indicates that the strength of recommendations, mediated by specific health poli-
cies facilitating screening, may indeed contribute to variation.
Introduction
Patient, provider and healthcare system characteristics may influence access to healthcare and
can be defined in terms of personal, financial and organizational barriers and facilitators [1].
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Regional variation of healthcare utilization is one indicator of unequal access [2]. However,
such variation may also be related to the characteristics of the service itself–whether it is prefer-
ence-sensitive, how convincing the evidence is for the service’s effect on health outcomes, and
whether it is known and accepted by providers and patients [3]. High quality of the available
guidelines and supporting evidence may facilitate the service’s implementation and reduce
variation in utilization [4].
Analysis of cancer screening utilization offers an opportunity to explore the impact of evi-
dence-based guidelines on the variation of the utilization of healthcare services. All cancer
screening services have broadly the same goal–detection of a symptomless early-stage cancer.
Target populations are often defined by sex and age criteria only. However, cancer screening
services differ in the available evidence of their impact on health outcomes. For example, colo-
rectal cancer screening is recommended routinely as it has been shown to reduce mortality
[5], breast cancer screening is often recommended, but the balance of benefits and harms is
debated in Switzerland and worldwide [6,7], and routine screening of prostate cancer is dis-
couraged by Swiss and European guidelines due to lacking evidence [8–10]. Potentially, differ-
ences in supporting evidence may lead to different utilization and regional variation patterns.
Relevant barriers and facilitators of access that should be controlled to observe the effect of
guidelines and evidence include regional policies of promotion and reimbursement rules [11].
In Switzerland, colorectal, breast and prostate cancer screening have different reimbursement
and promotion policies (Fig 1). Colorectal cancer screening is reimbursed nationally with
mandatory health insurance since 2013, and effectively no cantonal programs were running in
2014. Breast cancer screening is reimbursed in cantons with a screening program regardless of
the deductible chosen for the mandatory health insurance, with a 10% out-of-pocket copay-
ment, and promoted by personal invitation letters [12]. Prostate cancer screening is not rou-
tinely reimbursed, unless indicated after a shared-decision making process [9].
Other aspects of access to care, such as service availability and personal socioeconomic
characteristics, could drive variation in cancer screening utilization [13,14]. Similarly, the
publication of trial results and guidelines has been shown to influence utilization rates [15].
However, the effects of modifiers of access and the evidence for screening services are rarely
investigated in combination. In Switzerland few studies have investigated the geographic varia-
tion in breast cancer screening utilization either at the federal [16] or regional levels [17,18]
Fig 1. Screening for colorectal, breast and prostate cancer: Recommendations and reimbursement in Switzerland in 2014. FOBT–fecal occult
blood test, PSA–prostate specific antigen. a breast cancer screening is often recommended but the balance of benefits and harms is debated in
Switzerland and worldwide. b recommended age range (50–69 or 50–74) depends on the canton. c for colorectal cancer screening, programs in two
cantons were introduced on July 1, 2014, and were effective from 2015. For breast cancer screening, cantons with a program effective from the
beginning of 2014 are depicted in S1 Fig. d co-pay was covered in cantons of Jura andWallis in 2014.
https://doi.org/10.1371/journal.pone.0231409.g001
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and only one study has explored the variation of colorectal cancer screening utilization across
primary care practices [19]. Therefore, evidence is lacking about how utilization and its
regional variation compare across multiple cancer screening services.
We aimed to assess the influence of different modifiers of access and available evidence-
based guidelines on the utilization of cancer screening services. Specifically, we aimed to 1)
investigate utilization levels of colorectal, breast and prostate cancer screening in Switzerland,
2) identify potential influencing demographic, insurance, clinical and regional factors, and 3)
explore whether the relevant clinical guidelines may additionally contribute to explaining the
levels and variation of utilization observed across the screening services. We expected to see
less unexplained geographic variation when a service is strongly and routinely recommended
(i.e., colonoscopy for colorectal cancer screening), and more variation when screening is not
routinely recommended (i.e., prostate cancer screening).
Methods
Data source
We analyzed administrative claims data of a major Swiss insurer (Helsana Insurance Group),
covering the claims to the mandatory health insurance of approximately 1.2 million people
(15% of the Swiss population). The database included information on enrollees’ sociodemo-
graphics, such as sex, age and the language region (German, French or Italian), choice of insur-
ance characteristics, and details on reimbursed medical services, provided between January 1,
2014, and December 31, 2014. We excluded enrollees with incomplete insurance coverage or
not surviving until the end of 2014, asylum seekers, persons living outside Switzerland, Hel-
sana employees, and persons living in nursing homes and receiving lump-sum reimbursement
(which could mask individual medication claims).
Basic health insurance is mandatory in Switzerland and is provided by private insurers. The
benefit package is defined nationally, and includes all appropriate and cost-effective inpatient
and outpatient services. Persons can choose between different annual deductibles (ranging
from 300 to 2,500 Swiss Francs), with higher deductible resulting in lower monthly premiums.
Persons can opt for supplementary health insurance (covering some additional healthcare ser-
vices, such as alternative medicine or dental care) and supplementary inpatient hospital care
insurance (adding benefits such as single room accommodation). Persons can also choose a
managed care plan for smaller premiums, which requires that a general practitioner or tele-
medicine provider is the first contact for each new health problem.
Population
The eligible population was defined separately for each cancer screening service, considering
the relevant Swiss and international clinical guidelines. National and European guidelines
valid in 2014 were identified through relevant medical societies. National and cantonal reim-
bursement policies were characterised based on publicly available information (Fig 1).
Colorectal cancer screening was recommended and reimbursed for 50–69 years old per-
sons: either colonoscopy every ten years or fecal occult blood test (FOBT) every two years [12].
Breast cancer screening was recommended and reimbursed in cantons with an organized
cantonal screening program: mammography every two years [12]. Women between ages 50–
69 years (in cantons of Grisons, St. Gallen) or 50–74 years (in cantons of Bern, Fribourg,
Geneva, Jura, Neuchâtel, Thurgau, Vaud, Valais) were systematically invited to participate in
2014 [12]. We analyzed the female population aged 50–74 in this study.
Prostate cancer screening with prostate specific antibody (PSA) test was not recommended
routinely, and could be indicated only after considering personal risk factors and preferences
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in a shared decision making process [9]. Recommended age limits and frequency of screening
were not strictly defined, but age from 50 to 70 was mentioned as a reasonable range [9].
We did not exclude persons based on comorbidities or history of cancer. Due to limited
clinical data available in the claims datasets, it would not be possible to identify all such per-
sons, and imprecise exclusion criteria could introduce bias. However, we did adjust in the mul-
tilevel models for available clinical characteristics.
Outcome and explanatory variables
In our study, screening service implied that a test, suitable for screening, was used for an eligible
person, regardless of the indication. This means that tests done for diagnostic or follow-up rea-
sons were also included. This decision was made partly because indications (i.e., screening,
diagnostic testing due to certain symptoms present, or follow-up after clinical disease) are not
registered in the claims data, and partly because a diagnostic or follow-up test may additionally
function as an opportunistic screening.
We classified patients as receiving screening if a related claim was registered in 2014. The
screening services analyzed were mammography for breast cancer, PSA testing for prostate
cancer, and colonoscopy for colorectal cancer. For colorectal cancer, FOBT is a valid alterna-
tive. However, it is complicated to pool both tests together for combined analysis because
screening frequency is different (Fig 1) and colonoscopy is also recommended as a follow up
for a positive FOBT result. Thus, we restricted our main analysis to colonoscopy, which is used
by more persons in Switzerland [19]. FOBT utilization was analyzed separately, and we present
the results and their discussion in S2 Appendix.
We considered socio-demographic and clinical characteristics, and area of living at the
beginning of 2014, as explanatory variables. Health insurance characteristics analyzed were
whether any supplementary health insurance or supplementary hospital insurance was pres-
ent, whether enrollees had registered with a managed care model, and the chosen level of
deductible. Pharmaceutical cost group (PCG) categories derived from outpatient drugs pre-
scribed in 2013 were used as proxies for comorbidities [20]. PCGs representing cancer and
inflammatory bowel disease (IBD) were considered as separate binary variables, and the total
number of the other PCGs as ordinal variables. We further defined indicators of major colon,
breast and prostate diseases, based on inpatient diagnoses and procedures, and outpatient pro-
cedures and medications in 2013. Regional variables used were the purchasing power index
measured on a zip code level (centered at 100 as the mean value for the Swiss population) and
urban vs. rural residence. Cantons were grouped for the analysis of breast cancer screening by
the provision of a screening program in 2014. In a sensitivity analysis, cantons were also
grouped in this way for analysis of prostate cancer screening variation. Patients were assigned
to 106 Swiss MobSpat (“mobilité spatiale”) regions, defined by the Swiss Federal Statistical
Office [21], according to their place of residence. MobSpat regions have already been used for
research of the geographic variation of healthcare services in Switzerland previously [22].
The specific definitions of clinical variables used are provided in S1 Table.
Statistical analysis
We first calculated descriptive statistics of the populations grouped by utilization of the appli-
cable screening service. We estimated the overall screening utilization for Switzerland by
weighting the cantonal utilization by the total cantonal population in 2014, as the market share
of Helsana differs slightly across cantons.
Second, we ran a multilevel multivariable logistic regression model for each screening ser-
vice, with pre-specified variables as fixed person level effects, and random intercepts for the
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106 Swiss MobSpat regions. We included age as a cubic term in the models. The reporting of
the marginal effects in multilevel model would have been limited, thus we present the effects
from multivariable logistic regression models with the same covariates.
Third, we explored the geographic variation of screening utilization. We first mapped the
unadjusted utilization by MobSpat region. Spatial autocorrelation of regional utilization levels
was then analyzed with global Moran’s I statistic [23,24]. Moran’s I typically ranges from 1
(neighboring regions are more similar than distant regions) to 0 (spatial distribution of utiliza-
tion values is random) to -1 (neighboring regions are less similar than distant regions). We
then calculated median odds ratios (MOR) for the MobSpat level to estimate the degree of geo-
graphic random variation [25,26]. MOR converts the level of variation remaining after multi-
variable adjustment to the odds ratio (OR) scale, and thus can be directly compared to the
fixed-effects. MOR can be interpreted as the median odds of receiving the screening service if
an otherwise equal patient would be residing in a different MobSpat region with a higher rate
of screening utilization. MOR is always equal or above one because regions of higher utiliza-
tion are compared to regions of lower utilization. To examine whether clustering was still pres-
ent in the residuals of the multilevel models, they were aggregated per MobSpat region,
mapped, and spatial autocorrelation was again evaluated with the global Moran’s I statistic.
The degree of unexplained geographic variation (MOR and Moran’s I) after the multivari-
able adjustment was compared between cancer screening services in terms of the associated
evidence and guideline recommendations strength (Fig 1).
Statistical analyses were performed with R 3.4.4 [27], STATA 14.2, and MLwiN 3.01 [28]
integrated in STATA. Mapping was performed with QGIS 2.18.9 [29], and spatial clustering
analysis with GeoDa 1.12 [30]. P values<0.05 were considered statistically significant.
All procedures performed in the study were in accordance with the ethical standards of the
1964 Helsinki declaration and its later amendments. Study data were anonymized before anal-
ysis. According to the national ethical and legal regulations, ethical approval was not required
for this type of retrospective study. This was confirmed by a waiver of the competent ethics
committee (Kantonale Ethikkommission Zürich, dated January 11, 2017).
Results
Utilization levels of cancer screening
In the year 2014, Helsana enrollees eligible for the analyses of colorectal cancer, breast cancer
and prostate cancer screening comprised 276 387, 178 145 and 145 874 individuals, respec-
tively. Of these, 5.9% received colonoscopy, 20.9% mammography, and 28.4% PSA testing.
After weighting by the total cantonal populations, the estimated annual screening probabilities
in Switzerland were 8.1% for colonoscopy, 22.3% for mammography and 31.3% for PSA test-
ing. Considering recommended screening intervals (colonoscopy once in ten, mammography
once in two years) and based on simple probability-rate-probability conversions (assuming
constant screening rates) [31], approximately 57% of the eligible populations would receive
colonoscopy, and approximately 40% breast cancer screening, in total.
Socio-demographic, insurance preference and clinical characteristics of the populations are
shown in Table 1. The proportions of persons with urban residence, supplementary insurance,
managed care, and a high deductible level were similar among persons receiving each cancer
screening services, as was the number of PCGs present. In contrast, the screened populations
were rather different in terms of linguistic regions. For example, there were more persons
from French-speaking regions among persons receiving mammography than among those
receiving colonoscopy or PSA testing.
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Multilevel modelling of cancer screening utilization
Multilevel logistic regression results for the utilization of each cancer screening service are
shown in Table 2. Persons living in areas with higher purchasing power and urban areas were
more likely to receive screening. French- and Italian-speaking regions were more likely than
German regions to receive breast and prostate, but not colorectal cancer screening. Higher
deductible level was consistently associated with smaller odds of screening (CHF 2500 vs CHF
300: 0.63 [0.60–0.67] for colorectal cancer screening, 0.68 [0.65–0.71] for breast cancer screen-
ing, 0.56 [0.54–0.59] for prostate cancer screening utilization), while supplementary health
insurance, supplementary inpatient hospital care insurance and participation in a managed
care plan were associated with more screening.
The presence of PCG comorbidities and specific diseases was associated with a higher prob-
ability of receiving screening. Age had a non-linear effect on screening probability (marginal
Table 1. Characteristics of eligible population receiving cancer screening services in 2014.
Colorectal (N = 276 387)a Breast (N = 178 145) Prostate (N = 145 874)
Screening service provided No Yes No Yes No Yes
N 260010 16377 140882 37263 104516 41358
% of all eligible 94.1 5.9 79.1 20.9 71.6 28.4
Female (%) 134212 (51.6) 8463 (51.7)
Age (mean (SD)) 58.53 (5.84) 59.45 (5.80) 61.22 (7.27) 60.35 (6.97) 58.30 (6.13) 61.25 (6.03)
Purchasing power index on zip code level (mean (SD)) 101.62 (22.02) 103.50 (23.48) 101.91 (22.23) 101.14 (22.11) 101.52 (21.87) 102.09 (23.05)
Urban (%) 198011 (76.2) 12964 (79.2) 109070 (77.4) 28976 (77.8) 78072 (74.7) 32110 (77.6)
Language (%)
German 201483 (77.5) 12704 (77.6) 112107 (79.6) 24453 (65.6) 83972 (80.3) 29951 (72.4)
French 39708 (15.3) 2383 (14.6) 18328 (13.0) 9261 (24.9) 14099 (13.5) 7275 (17.6)
Italian 18819 (7.2) 1290 (7.9) 10447 (7.4) 3549 (9.5) 6445 (6.2) 4132 (10.0)
Supplementary insurance (%) 192895 (74.2) 12568 (76.7) 108376 (76.9) 29191 (78.3) 74447 (71.2) 31712 (76.7)
High deductible (�500 CHF) (%) 73544 (28.3) 3267 (19.9) 31493 (22.4) 6216 (16.7) 37720 (36.1) 8366 (20.2)
Managed care (%) 132358 (50.9) 8317 (50.8) 70055 (49.7) 19088 (51.2) 53231 (50.9) 20918 (50.6)
Supplementary hosp. ins. (%) 57081 (22.0) 4584 (28.0) 35974 (25.5) 10694 (28.7) 19071 (18.2) 10354 (25.0)
Comorbidities (%)
0 121697 (46.8) 5771 (35.2) 57733 (41.0) 12691 (34.1) 55868 (53.5) 12586 (30.4)
1 52328 (20.1) 3674 (22.4) 29616 (21.0) 8528 (22.9) 18727 (17.9) 8942 (21.6)
2 38632 (14.9) 2885 (17.6) 22033 (15.6) 6546 (17.6) 14110 (13.5) 8840 (21.4)
3+ 47353 (18.2) 4047 (24.7) 31500 (22.4) 9498 (25.5) 15811 (15.1) 10990 (26.6)
PCG Cancer 2854 (1.1) 334 (2.0) 1891 (1.3) 903 (2.4) 865 (0.8) 537 (1.3)
PCG IBD 1253 (0.5) 290 (1.8)
Major colon disease (%) 804 (0.3) 254 (1.6)
Major breast disease (%) 1192 (0.8) 2185 (5.9)
Major prostate disease (%) 658 (0.6) 1585 (3.8)
In canton with programb 50739 (36.0) 19193 (51.5)
SD–standard deviation, CHF–Swiss francs, Supplementary hosp.ins.–supplementary inpatient hospital care insurance, PCG–pharmaceutical cost group, IBD–
inflammatory bowel disease.
a Eligible persons who received FOBT (fecal occult blood test) but not colonoscopy are excluded. Only colonoscopy is considered as screening service here. FOBT is
reviewed separately in S2 Appendix.
b Cantonal-level coordinated breast cancer screening program.
https://doi.org/10.1371/journal.pone.0231409.t001
PLOS ONE Variation of colorectal, breast and prostate cancer screening activity in Switzerland
PLOSONE | https://doi.org/10.1371/journal.pone.0231409 April 16, 2020 6 / 15
effects depicted in S1 Appendix). Residing in a canton with a coordinated program was associ-
ated with an OR for breast cancer screening of 1.80 [1.66–1.97]. In the model of prostate can-
cer screening utilization, the presence of a breast cancer screening program in the canton of
residence resulted in a significant OR of 1.15 [1.07–1.25], with other effect estimates remaining
stable.
Table 2. Multilevel model estimates (odds ratio) and spatial clustering analysis for cancer screening services utilization in 2014.
Colorectal Breast Prostate
Female 0.93 [0.90–0.96] N/A N/A
Age 0.17 [0.17–0.17] 0.15 [0.15–0.15] 1.17 [1.17–1.18]
Age2 (age squared) 1.03 [1.03–1.03] 1.03 [1.03–1.03] 1.00 [1.00–1.00]
Age3 (age cubed) 1.00 [1.00–1.00] 1.00 [1.00–1.00] 1.00 [1.00–1.00]
Purchasing power index 1.25 [1.16–1.38] 1.09 [1.01–1.18] 1.20 [1.12–1.28]
Urban 1.07 [1.02–1.12] 1.06 [1.03–1.11] 1.10 [1.07–1.14]
Language
German Reference Reference Reference
French 0.86 [0.79–0.94] 1.65 [1.50–1.81] 1.38 [1.25–1.53]
Italian 1.11 [0.98–1.27] 1.69 [1.43–2.01] 1.50 [1.28–1.74]
Supplementary insurance 1.05 [1.00–1.10] 1.14 [1.10–1.17] 1.18 [1.14–1.22]
Deductible level, CHF
300 Reference Reference Reference
500 0.92 [0.88–0.95] 0.93 [0.90–0.96] 0.91 [0.89–0.94]
1000 0.81 [0.75–0.88] 0.82 [0.77–0.88] 0.74 [0.70–0.77]
1500 0.73 [0.68–0.78] 0.74 [0.71–0.78] 0.62 [0.60–0.65]
2000 0.63 [0.54–0.72] 0.68 [0.60–0.77] 0.60 [0.55–0.66]
2500 0.63 [0.60–0.67] 0.68 [0.65–0.71] 0.56 [0.54–0.59]
Managed care 1.12 [1.08–1.15] 1.13 [1.10–1.16] 1.13 [1.11–1.15]
Supplementary hospital care insurance 1.34 [1.29–1.40] 1.29 [1.25–1.32] 1.36 [1.33–1.40]
Comorbidities
0 Reference Reference Reference
1 1.30 [1.24–1.36] 1.26 [1.22–1.30] 1.66 [1.61–1.71]
2 1.31 [1.25–1.38] 1.30 [1.25–1.35] 1.90 [1.84–1.95]
3+ 1.45 [1.38–1.52] 1.30 [1.25–1.34] 1.83 [1.79–1.89]
PCG Cancer 1.37 [1.21–1.54] 1.14 [1.03–1.24] 0.96 [0.89–1.04]
PCG IBD 2.81 [2.47–3.19] N/A N/A
Major colon disease 3.51 [3.03–4.06] N/A N/A
Major breast disease N/A 7.44 [6.90–8.00] N/A
Major prostate disease N/A N/A 3.75 [3.54–3.99]
In canton with programa N/A 1.80 [1.66–1.97] N/A
Spatial variation statistics
MOR 1.16 [1.12–1.20] 1.20 [1.16–1.25] 1.24 [1.20–1.30]
Moran’s I of raw utilization 0.216 (p<0.001) 0.621 (p<0.001) 0.552 (p<0.001)
Moran’s I of residuals 0.083 (p = 0.074) 0.070 (p = 0.104) 0.492 (p<0.001)
CHF–Swiss francs, PCG–pharmaceutical cost group, IBD–inflammatory bowel disease, MOR–median odds ratio.
The comorbidities variable did not include PCG cancer and PCG IBD. Odds ratio estimates in grey are not statistically significantly different from 1. For colorectal
cancer screening modelling, only colonoscopy is considered as the outcome of interest. FOBT (fecal occult blood test) and the combination of both tests is excluded and
is reviewed separately in S2 Appendix.
a Cantonal-level coordinated breast cancer screening program.
https://doi.org/10.1371/journal.pone.0231409.t002
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Geographic pattern of screening utilization
Spatial clustering was observed in the raw regional utilization of all screening services (Fig 2),
with stronger clustering for breast (Moran’s I 0.62, p<0.001) and prostate (0.55, p<0.001)
than for colorectal cancer screening (0.22, p<0.001) (Table 2). Western and eastern regions of
Switzerland had higher raw mammography utilization, while PSA test utilization was some-
what higher in the west and south.
The MOR after multilevel modelling for the regional level was 1.24 [1.20–1.30] for prostate
cancer screening and slightly smaller for breast (1.20 [1.16–1.25]) and colorectal (1.16 [1.12–
1.20]) cancer screening. Spatial clustering of multilevel model regional level residuals of
screening utilization (Fig 3) was insignificant for colorectal and breast cancer screening, but
high for prostate cancer screening (Moran’s I 0.49, p<0.001). Regions with residuals of pros-
tate cancer screening utilization indicating significantly higher use were situated mostly in the
west and south-east of Switzerland (Fig 2). Adding the presence of breast cancer screening pro-
gram in the model of prostate cancer screening utilization slightly reduced the spatial cluster-
ing (Moran’s I) of the model’s regional residuals.
Discussion
The absolute estimated levels of colorectal, breast and prostate cancer screening annual utiliza-
tion in Switzerland in 2014 were 8.1% (colonoscopy), 22.3% (mammography) and 31.3% (PSA
testing), respectively. Insurance characteristics, such as lower deductibles, supplementary
insurance, being enrolled in a managed care plan and presence of comorbidities were associ-
ated with higher screening utilization. Cantons with organized breast cancer screening pro-
grams were associated with more breast cancer screening, whereas the effect of language was
inconsistent across the services. Geographic variation, as reflected in MOR, was highest for
prostate and lowest for colorectal cancer screening. We observed significant geographic
Fig 2. Raw utilization of cancer screening services in eligible population in Switzerland in 2014. A–colorectal
cancer screening, B–breast cancer screening, C–prostate cancer screening.
https://doi.org/10.1371/journal.pone.0231409.g002
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clustering in prostate cancer screening even after influencing factors had been controlled for,
signaling potentially unwarranted variation.
We estimated that approximately 57% of the eligible population would receive colorectal
cancer screening and 40% breast cancer screening, within ten and two years respectively, as
recommended by guidelines (such an estimate was not possible for prostate cancer screening,
as the recommended testing frequency is personalized). Compared to the rates of screening in
European countries with organized programs, our estimate for colorectal screening was higher
than the reported average of approximately 20% [32], and the estimate for breast cancer
screening lower than the reported average of approximately 50% [33].
We estimated higher screening utilization in Switzerland than other studies. In a study of
primary care patients within the Swiss Sentinel Surveillance Network in 2017, 41% of patients
aged 50 to 75 reported colonoscopy in the last ten years [19]. Only 13.3% of women aged 50 to
69 reported mammography in the last 12 months in the Swiss Health Survey in 2012 [16]. In a
voluntary database of routine electronic medical records of Swiss primary care practices,
11.7% of men aged 55 to 75 without prostate disease or symptoms received PSA testing in
2010–2017 [15]. Screening utilization estimates may differ between these and our study partly
due to differences in design, such as the age range of included persons eligible for screening.
Also, we did not exclude potentially indicated (diagnostic and follow-up) tests. Information
collection methods were also different. Whereas we used claims data, the other studies used
self-reported information or electronic medical records. Potentially, self-reported data could
be prone to information, recall and social desirability biases, and electronic health records at
the primary care practice could miss tests done elsewhere, e.g. by a urologist. Finally, the year
of data collection differed across the previous studies from 2010 to 2017, and the observation
time window from one to ten years.
Fig 3. Multilevel models’ regional residuals of cancer screening services utilization, significantly different from national mean.
A–colorectal cancer screening, B–breast cancer screening, C–prostate cancer screening.
https://doi.org/10.1371/journal.pone.0231409.g003
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Effect of explanatory variables
The effect of explanatory variables on screening utilization reflects different barriers and facili-
tators of access to care. Persons with comorbidities, as reflected by the PCGs and clinical indi-
cators of disease, were more likely to be screened. PCGs and disease indicators signal not only
worse health, but also more contact with healthcare services providers. In fact, healthcare ser-
vices utilization (such as a recent visit to a physician) has been associated with higher screening
rates [14]. In contrast to this, worse self-reported health or comorbidities were associated with
lower odds of screening [14], even though the effect of different comorbidities might not be
the same [34]. Thus, being assigned to PCG or other indicators of diseases from the claims
data could constitute both barriers (poor health) and facilitators (receiving healthcare services)
to screening. Additionally, more diagnostic and follow-up tests are provided for less healthy
people, which would have been observed as screening services in our study. Finally, persons
with poorer health status often choose lower deductibles, but also use more health services–
leading to a mix of barriers and facilitators.
Lower deductibles, supplementary insurance and urban or wealthier residence were consis-
tently associated with more screening. Health insurance with higher deductibles has been
reported to lead to foregoing care in Switzerland, and thus constitute a financial barrier [35].
Participation in a managed care model (for more details see [36]), was associated with more
screening–potentially as the care provided is more coordinated and guideline-compliant, or as
this model is selected by more health aware persons. Urban residence, better access to health-
care (e.g., shorter distance and higher physician density) [13], as well as higher socioeconomic
status or income have been shown to increase the odds of screening both at individual and
regional levels [37–39]. Self-reported barriers to screening utilization include lack of aware-
ness, negative attitudes towards screening and socioeconomic factors, and some of the facilita-
tors are public education and physician recommendation [40]. These barriers are indeed
partly reflected in our observed association of screening utilization with sociodemographic
and insurance characteristics.
Cantonal breast cancer screening programs were a strong driver of screening utilization
(Table 2), an effect also observed by Fenner et al. [16]. The effect of language region on screen-
ing utilization might reflect differences in acceptance or local health promotion programs.
However, the effect of specific language regions was not consistent across screening services
(Table 2). In previous studies, Braun et al. found no effect of language region on the utilization
of colorectal cancer screening [19], whereas Eichholzer et al. observed a higher utilization of
breast cancer screening in French speaking cantons of Switzerland [18].
Geographic variation within and across screening services
We selected three cancer screening services reflecting different degrees of certainty in terms of
their evidence of benefit-to-harm balance, impact on health outcomes, and clinical guidelines
recommending them. We expected to observe a correlation with different degrees of regional
variation (MOR) and, potentially, different degrees of unexplained spatial clustering patterns
(Moran’s I). The highest MOR of 1.24 was observed for prostate cancer screening, which is not
routinely recommended. The MobSpat-level residuals in the multilevel prostate cancer model
were the only ones that remained significantly spatially autocorrelated, signaling that a relevant
part of regional variation was not explained (Fig 3). Breast cancer screening, which is recom-
mended but debated, had slightly lower residual geographic variation, and the variation was
lowest for colorectal cancer screening, which is consistently recommended in guidelines. The
interpretation of this trend needs to consider that screening services also differ by other char-
acteristics, not considered in our models. For example, they are delivered by different
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specialists (e.g., PSA test often by primary care physicians and colonoscopy by gastroenterolo-
gists); reimbursement policies are different (e.g., screening colonoscopy covered by mandatory
health insurance while screening mammography only covered, and exempt from deductible,
in cantons with a screening program); the eligible populations are of different sexes. Still, this
is the first study indicating a relationship between the strength of recommendations and geo-
graphic variation of screening utilization, warranting further exploration.
The unexplained geographic variation seen in prostate cancer screening could have sev-
eral reasons. First, prostate cancer screening recommendation in both Swiss [9] and Euro-
pean guidelines [10] are conditional, and could be considered weak and sensitive to patient
preferences, according to the GRADE approach [41]. This recommendation could be inter-
preted as discouraging routine use, but it could also be interpreted as encouraging screening
after a shared-decision making process. Second, even after adjusting for language and other
covariates, the observed clusters of high utilization partly coincided with the presence of
breast cancer screening programs (Fig 2 and S1 Fig). In fact, adding an indicator for the
presence of a cantonal breast cancer screening program to the model resulted in a signifi-
cant OR and slightly reduced spatial clustering (Moran’s I) of the model’s regional residu-
als. This could mean that breast cancer screening programs encourage gender-specific or
any cancer screening more broadly. It has already been observed that regional utilization of
prostate cancer screening could be partly explained by the utilization of another cancer
screening [42]. However, we did not observe a comparable pattern for colorectal cancer
screening. Third, we may have missed important locally specific influencing factors, such as
patient and provider preferences. In addition, local spill-over effects may be taking place
among neighboring MobSpat regions, that is, patient and provider preferences may be
more similar or even stimulate each other across neighboring MobSpat regions. However,
we believe that the effect estimates of the currently included covariates would not change
significantly, as they were consistent with the models of colorectal and breast cancer screen-
ing utilization.
Limitations
Our study has several limitations. First, we used claims data from a single, albeit largest in
Switzerland, health insurer. Although the population of Helsana insured persons is slightly
older than the general Swiss population [43], the benefits package of the mandatory health
insurance is defined at the federal level, and patients can choose their healthcare providers
regardless of insurance provider. Second, claims data have limited clinical information, such
as outpatient diagnoses, and lack past claims if the patient was previously insured by another
company. For this reason, we could not distinguish diagnostic and follow-up use of screening
services. Clinically indicated and screening tests could be associated with different barriers and
facilitators. In our study, a clinical indicator of related diseases was associated with more
screening. This association could signal that patients with such diseases receive more diagnos-
tic and follow-up tests, not screening. Thus, not excluding clinically indicated tests could result
in an overestimation of screening utilization. On the other hand, our primary interest was the
variation in utilization within and between the screening services. We would not expect a suffi-
ciently large degree of geographic variation in, e.g., the presence of prostate disease and symp-
toms, to explain the observed clustering of PSA test utilization. Third, services paid out-of-
pocket were not recorded. This could underestimate the utilization of less expensive screening
procedures (PSA and FOBT testing), whereas mammography and colonoscopy are not likely
to be paid out of pocket. Finally, we could not analyze the influence of screening service pro-
vider, which could be a significant driver of regional variation [44].
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Further research implications
This study raises further questions. As new cantons are introducing screening programs,
patients may become more aware of reimbursement policies and guidelines may change, we
plan to investigate the effect on screening utilization with multiple temporal cross-sections of
the following years. For example, the mean level of prostate cancer screening utilization was
shown to have changed in Switzerland following the publication of trial results and guidelines
[15], but the change in geographic variation is not known. The regional density of relevant spe-
cialty physicians could explain some further variation. Diagnostic and screening use of the ser-
vices could be better differentiated and explained by specific facilitators and barriers, by
linking clinical information or running subgroup analyses. In general, merging claims data
with clinical or patient preferences data would likely increase the explanatory power of the
models. As some regional variation remains unexplained, we can only hypothesize if it is
related to further regional, provider or patient characteristics.
Conclusions
We observed that the absolute levels of colorectal, breast and prostate cancer screening annual
utilization in 2014 in Switzerland were 8.1%, 22.3% and 31.3%, respectively. Insurance charac-
teristics, such as low deductibles, supplementary health insurance and managed care plan, were
consistently associated with higher screening utilization levels, potentially signaling modifiable
barriers and facilitators. Breast cancer screening programs were shown to be successful in pro-
moting screening utilization–possibly because they increase awareness of screening benefits
and reduce financial barriers. After controlling for explanatory variables, spatial clustering,
indicating potentially unwarranted variation, was present only in prostate cancer screening,
which is not recommended routinely without explicit shared decision-making. Prostate cancer
screening utilization also had the highest regional level variation, while colorectal cancer
screening had the lowest, hinting at the potential role of strong recommendations and evidence
in decreasing the variation of services utilization. The reasons for the variation of the prostate
cancer screening utilization could be further investigated by adding provider level characteris-
tics and patient preference information. This first cross-comparison of different cancer screen-
ing patterns indicates that the strength of guidelines, mediated by the implementation of
specific health policies facilitating screening, may indeed influence the degree of variation.
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